As I was reading the description on the clinical trials web site, I noticed that Brilacidin plus the SOC (Standard Of Care is Remdesivir?) was being infused, versus the "Placebo" arm which is SOC alone? So IF the SOC is Remdesivir, then we will have a pretty good data set to compare the relative efficacy of Brilacidin to Remdesivir, don't you think?